Li Tianjie, Qian Xinye, Liu Jinyang, Xue Feng, Luo Jing, Yao Guanqun, Yan Jun, Liu Xiaodong, Xiao Bo, Li Jianxing
School of Clinical Medicine, Tsinghua University, Beijing, China.
Department of Urology, Beijing Tsinghua Changung Hospital, Beijing, China.
Front Oncol. 2023 Jul 21;13:1210673. doi: 10.3389/fonc.2023.1210673. eCollection 2023.
The immune checkpoint inhibitor (ICI) is a promising strategy for treating cancer. However, the efficiency of ICI monotherapy is limited, which could be mainly attributed to the tumor microenvironment of the "cold" tumor. Prostate cancer, a type of "cold" cancer, is the most common cancer affecting men's health. Radiotherapy is regarded as one of the most effective prostate cancer treatments. In the era of immune therapy, the enhanced antigen presentation and immune cell infiltration caused by radiotherapy might boost the therapeutic efficacy of ICI. Here, the rationale of radiotherapy combined with ICI was reviewed. Also, the scheme of radiotherapy combined with immune checkpoint blockades was suggested as a potential option to improve the outcome of patients with prostate cancer.
免疫检查点抑制剂（ICI）是一种很有前景的癌症治疗策略。然而，ICI单药治疗的疗效有限，这主要归因于“冷”肿瘤的肿瘤微环境。前列腺癌是一种“冷”癌，是影响男性健康的最常见癌症。放射治疗被认为是最有效的前列腺癌治疗方法之一。在免疫治疗时代，放射治疗引起的抗原呈递增强和免疫细胞浸润可能会提高ICI的治疗效果。在此，对放射治疗联合ICI的理论基础进行了综述。此外，还建议将放射治疗联合免疫检查点阻断作为一种潜在的选择，以改善前列腺癌患者的治疗结果。
